Home / Deep Research / Guanidinoacetate Methyltransferase Deficiency

Guanidinoacetate Methyltransferase Deficiency

Disease Pathophysiology Research Template

2026-02-23
Falcon MONDO:0012999 Model: Edison Scientific Literature 23 citations

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on: 1. Key concepts and definitions with current understanding 2. Recent developments and latest research (prioritize 2023-2024 sources) 3. Current applications and real-world implementations 4. Expert opinions and analysis from authoritative sources 5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available. Always prioritize recent, authoritative sources and provide specific citations for all major claims.

Disease Pathophysiology Research Template

Target Disease

  • Disease Name: Guanidinoacetate Methyltransferase Deficiency
  • MONDO ID: (if available)
  • Category: Genetic

Research Objectives

Please provide a comprehensive research report on the pathophysiology of Guanidinoacetate Methyltransferase Deficiency. Focus on the molecular and cellular mechanisms underlying disease progression.

Required Information

1. Core Pathophysiology

  • What are the primary pathophysiological mechanisms?
  • What molecular pathways are dysregulated?
  • What cellular processes are affected?

2. Key Molecular Players

  • Genes/Proteins: Which genes are causally involved or implicated?
  • Chemical Entities: What metabolites, drugs, or small molecules are relevant?
  • Cell Types: Which cell types are primarily affected?
  • Anatomical Locations: Which tissues/organs are involved?

3. Biological Processes (for GO annotation)

  • What biological processes (GO terms) are disrupted?
  • Consider: signaling pathways, metabolic processes, cellular responses, transport, etc.

4. Cellular Components

  • Where in the cell do key processes occur?
  • Consider: organelles, membrane compartments, extracellular space, etc.

5. Disease Progression

  • What is the sequence of events from initial trigger to clinical manifestation?
  • Are there distinct stages or phases?

6. Phenotypic Manifestations

  • What are the key clinical phenotypes?
  • How do they relate to the underlying mechanisms?

Citation Requirements

  • Cite primary literature (PMID preferred) for all mechanistic claims
  • Prioritize recent reviews and landmark papers
  • Include direct quotes where possible to support key statements

Output Format

Structure your response as a narrative that could be used to populate a disease knowledge base entry with: - Pathophysiology description - Gene/protein annotations with ontology terms (HGNC, GO) - Phenotype associations (HP terms) - Cell type involvement (CL terms) - Anatomical locations (UBERON terms) - Chemical entities (CHEBI terms) - Evidence items with PMIDs

Comprehensive Pathophysiology Research Report: Guanidinoacetate Methyltransferase (GAMT) Deficiency

Target disease and identifiers

Disease name and category: Guanidinoacetate methyltransferase (GAMT) deficiency; genetic, autosomal recessive disorder of creatine biosynthesis. (ream2023evidenceandrecommendation pages 1-3) Common alternate naming used in the literature: Cerebral creatine deficiency syndrome (CCDS) due to a creatine-synthesis defect. (alyazidi2024phenotypicandmolecular pages 1-2, binsfeld2026acnsdirectedaav9 pages 1-3) Key identifiers available in retrieved sources: - OMIM (disease): OMIM #612736 (as reported in a 2023 review table of creatine deficiency disorders). (mulik2023creatinedeficiencydisorders pages 2-3) - OMIM (gene): GAMT gene is cited as MIM #601240 in a 2023 Pediatrics newborn screening evidence review. (ream2023evidenceandrecommendation pages 1-3) MONDO ID: Not found in the retrieved full-text excerpts; therefore not reported here.

Executive summary (current understanding)

GAMT deficiency is caused by biallelic loss-of-function variants in GAMT (19p13.3), which encodes guanidinoacetate methyltransferase, the enzyme that catalyzes the final step of endogenous creatine biosynthesis by methylating guanidinoacetate (GAA) to creatine using S-adenosylmethionine as methyl donor. (mulik2023creatinedeficiencydisorders pages 1-2, marten2024longtermfollowup pages 1-2) The canonical biochemical signature is systemic and cerebral creatine depletion together with accumulation of guanidinoacetate in biofluids and brain. (ream2023evidenceandrecommendation pages 1-3, marten2024longtermfollowup pages 1-2) Disease mechanisms are increasingly framed as the combined effect of (i) creatine deficiency (impaired ATP buffering/energy shuttle) and (ii) GAA neurotoxicity, including evidence implicating altered GABAergic neurotransmission and seizure susceptibility. (marten2024longtermfollowup pages 1-2, khoja2022genetherapyfor pages 1-2) Clinically, the disorder is a neurodevelopmental encephalopathy with prominent developmental delay/intellectual disability, severe speech impairment, epilepsy, behavioral disturbances, and movement disorders; early/presymptomatic treatment is associated with substantially better neurodevelopmental outcomes, motivating newborn screening implementation. (ream2023evidenceandrecommendation pages 1-3, stockleripsiroglu2014guanidinoacetatemethyltransferase(gamt) pages 1-2, ream2023evidenceandrecommendation pages 3-4)

  1. Key concepts and definitions (core pathophysiology)

1.1 Creatine metabolism and “cerebral creatine deficiency” Creatine is a key metabolite for energy homeostasis via the creatine/phosphocreatine system that buffers and rapidly regenerates ATP during fluctuating demand. A 2023 evidence review describes creatine as “a critical energy source for cellular metabolism” and links GAMT deficiency to cerebral creatine depletion. (ream2023evidenceandrecommendation pages 1-3) In GAMT deficiency, creatine is low in plasma and brain, while guanidinoacetate is elevated in brain, CSF, blood, and urine. (ream2023evidenceandrecommendation pages 1-3) A frequently used clinical imaging definition of cerebral creatine deficiency is the reduction/absence of the creatine peak on proton magnetic resonance spectroscopy (1H-MRS); a 2023 review summarizes that GAMT deficiency shows “absent or markedly decreased Cr in brain 1H-MRS.” (mulik2023creatinedeficiencydisorders pages 2-3)

1.2 Enzymatic defect and pathway position Creatine is biosynthesized from arginine and glycine through two key steps: (i) AGAT produces guanidinoacetate (GAA), and (ii) GAMT methylates GAA to creatine. Loss of GAMT blocks this final step, causing creatine deficiency and GAA accumulation. (mulik2023creatinedeficiencydisorders pages 1-2, khoja2022genetherapyfor pages 1-2) A 2024 long-term follow-up report reiterates that GAMT uses S-adenosylmethionine (SAM) as the methyl donor in this conversion and that the consequence is “cerebral creatine depletion and accumulation of guanidinoacetate.” (marten2024longtermfollowup pages 1-2)

1.3 Dual-mechanism disease model: creatine deficiency plus GAA toxicity The 2023 Pediatrics review explicitly frames pathophysiology as low creatine plus “neurotoxic levels of guanidinoacetate.” (ream2023evidenceandrecommendation pages 1-3) Mechanistically, creatine deficiency is expected to impair neuronal energy buffering (creatine/phosphocreatine shuttle), whereas elevated GAA can exert direct neurotoxicity and pro-convulsant effects. (marten2024longtermfollowup pages 1-2, khoja2022genetherapyfor pages 1-2)

  1. Dysregulated molecular pathways and affected cellular processes

2.1 Dysregulated metabolic pathways - Creatine biosynthetic process / creatine metabolic process: loss of GAMT blocks endogenous creatine production, leading to low creatine in body fluids and brain. (mulik2023creatinedeficiencydisorders pages 1-2, marten2024longtermfollowup pages 1-2) - Guanidinoacetate (GAA) handling: precursor overproduction and/or impaired clearance leads to systemic and CNS accumulation. (ream2023evidenceandrecommendation pages 1-3) - One-carbon/methylation burden (conceptual mechanism): because GAMT consumes methyl groups from SAM, perturbations and/or therapeutic manipulation of guanidinoacetate can affect methyl balance; a 2023 review cautions about risks including “methyl group depletion” and “guanidinoacetate-driven hyperhomocysteinemia.” (mulik2023creatinedeficiencydisorders pages 2-3)

2.2 Cellular processes affected - Bioenergetic buffering / ATP homeostasis: creatine is required for rapid ATP regeneration via phosphocreatine; creatine deficiency is linked to impaired energy metabolism and neurodevelopmental dysfunction. (ream2023evidenceandrecommendation pages 1-3, khoja2022genetherapyfor pages 1-2) - Neurotransmission and excitability (GABAergic mechanisms): a 2024 follow-up paper cites mechanistic work indicating that “Guanidinoacetate (GAA) is a potent GABAA receptor GABA mimetic,” supporting a plausible direct mechanism for seizures and altered inhibitory neurotransmission in GAMT deficiency. (marten2024longtermfollowup pages 7-7) - Neurodevelopmental processes: a preclinical gene-therapy report notes creatine’s roles beyond energy buffering, including neurite growth and neurotransmission, consistent with developmental vulnerability of the CNS in GAMT deficiency. (khoja2022genetherapyfor pages 1-2)

  1. Key molecular players (genes/proteins, metabolites, cell types, tissues)

3.1 Genes and proteins (HGNC-style gene symbols) Primary causal gene - GAMT (guanidinoacetate methyltransferase): biallelic pathogenic variants cause disease; autosomal recessive inheritance. (ream2023evidenceandrecommendation pages 1-3) Pathway and related genes (frequently co-discussed in CCDS literature) - GATM (AGAT): upstream enzyme producing guanidinoacetate; relevant for understanding substrate-reduction therapies and differential diagnosis. (mulik2023creatinedeficiencydisorders pages 1-2, khoja2022genetherapyfor pages 1-2) - SLC6A8 (creatine transporter): not causal for GAMT deficiency, but central to creatine uptake and to broader “cerebral creatine deficiency syndromes” context; important for interpreting why oral creatine may incompletely restore CNS creatine. (mulik2023creatinedeficiencydisorders pages 1-2, khoja2022genetherapyfor pages 1-2) Variant interpretation / authoritative genomic curation - ClinGen curation efforts for CCDS genes (including GAMT) have produced 2024 recommendations for variant classification, supporting consistent interpretation of pathogenicity. (binsfeld2026acnsdirectedaav9 pages 1-3)

3.2 Chemical entities (CHEBI-style) Core metabolites - Creatine (Cr): deficient in plasma/CSF/brain and urine in GAMT deficiency; therapeutic replacement is a cornerstone. (mulik2023creatinedeficiencydisorders pages 2-3, marten2024longtermfollowup pages 1-2) - Guanidinoacetate / guanidinoacetic acid (GAA): accumulates systemically and in the CNS and is considered neurotoxic. (ream2023evidenceandrecommendation pages 1-3, marten2024longtermfollowup pages 1-2) - S-adenosylmethionine (SAM): methyl donor required by GAMT; relevant to methylation balance considerations. (mulik2023creatinedeficiencydisorders pages 1-2, marten2024longtermfollowup pages 1-2) Therapeutic small molecules/dietary agents used in practice - Creatine monohydrate: typical dosing in reviews ~400–800 mg/kg/day. (mulik2023creatinedeficiencydisorders pages 2-3, ream2023evidenceandrecommendation pages 3-4) - L-ornithine: used to reduce GAA synthesis by inhibiting AGAT (substrate reduction); dosing ranges described (e.g., 100–800 mg/kg/day). (ream2023evidenceandrecommendation pages 3-4) - Sodium benzoate: used in some regimens to reduce glycine availability (and thereby GAA synthesis); included in presymptomatic protocols. (ream2023evidenceandrecommendation pages 1-3, ream2023evidenceandrecommendation pages 3-4) - Protein/arginine-restricted diet: reduces precursor supply for GAA. (ream2023evidenceandrecommendation pages 1-3, mulik2023creatinedeficiencydisorders pages 2-3)

3.3 Cell types (CL-style) and tissues/anatomical locations (UBERON-style) CNS involvement is primary - Brain (UBERON: brain): cerebral creatine deficiency is detectable by 1H-MRS; clinical sequelae are neurological. (mulik2023creatinedeficiencydisorders pages 2-3, marten2024longtermfollowup pages 1-2) - Basal ganglia (UBERON: basal ganglion): reported MRI T2 hyperintensities in some cases. (marten2024longtermfollowup pages 1-2) Peripheral tissues relevant for metabolism and emerging therapies - Liver (UBERON: liver): frequently emphasized as a key site for creatine biosynthesis and a target for gene therapy approaches; a 2022 AAV strategy achieved pan-hepatic expression with systemic biochemical correction. (khoja2022genetherapyfor pages 1-2) - Heart/myocardium (UBERON: myocardium): gene therapy in a mouse model increased myocardial creatine. (khoja2022genetherapyfor pages 1-2) Cell-type specificity (current model) The literature increasingly emphasizes compartmentation of creatine synthesis/transport across tissues and (in the CNS) across cell types, supporting why deficiency manifests strongly in brain and why restoring brain creatine is challenging. (khoja2022genetherapyfor pages 1-2, binsfeld2026acnsdirectedaav9 pages 1-3)

  1. Biological processes and cellular components (for ontology annotation)

4.1 Candidate disrupted GO biological processes (mechanistically grounded) - Creatine biosynthetic process / creatine metabolic process (blocked GAMT-mediated methylation step). (mulik2023creatinedeficiencydisorders pages 1-2, marten2024longtermfollowup pages 1-2) - Guanidinoacetate metabolic process (pathologic accumulation). (ream2023evidenceandrecommendation pages 1-3, marten2024longtermfollowup pages 1-2) - Cellular energy homeostasis / ATP metabolic process (creatine described as critical for cellular energy metabolism). (ream2023evidenceandrecommendation pages 1-3, khoja2022genetherapyfor pages 1-2) - GABAergic synaptic transmission / regulation of membrane potential / seizure susceptibility (supported by evidence that GAA can act as a GABAA receptor mimetic). (marten2024longtermfollowup pages 7-7) - Neurodevelopmental processes (neurite outgrowth and neurotransmission roles of creatine, consistent with developmental phenotypes). (khoja2022genetherapyfor pages 1-2)

4.2 Candidate GO cellular components - Cytosol (site of creatine/phosphocreatine buffering reactions broadly discussed in creatine biology). (khoja2022genetherapyfor pages 1-2) - Mitochondrial-associated energy-transfer interface (conceptual location for creatine kinase energy shuttle; described as an energy shuttle between ATP production and utilization sites). (khoja2022genetherapyfor pages 1-2) - Synapse / postsynaptic membrane (implicated by GABAA receptor mechanism for GAA). (marten2024longtermfollowup pages 7-7)

  1. Disease progression: sequence of events from trigger to clinical manifestations

5.1 Initiation - Genetic trigger: biallelic pathogenic variants in GAMT lead to deficient GAMT enzymatic activity. (ream2023evidenceandrecommendation pages 1-3, mulik2023creatinedeficiencydisorders pages 1-2) - Early life masking: newborns may be asymptomatic at birth, attributed to in utero/placental creatine transfer, with symptoms developing later without treatment. (ream2023evidenceandrecommendation pages 1-3)

5.2 Early biochemical derangements - Reduced conversion of GAA to creatine leads to systemic and cerebral creatine depletion and GAA accumulation in biofluids and brain/CSF. (ream2023evidenceandrecommendation pages 1-3, marten2024longtermfollowup pages 1-2)

5.3 Cellular dysfunction and network-level consequences - Energetic stress: reduced creatine/phosphocreatine buffering capacity in high-energy tissues (notably brain) contributes to neurodevelopmental dysfunction. (ream2023evidenceandrecommendation pages 1-3, marten2024longtermfollowup pages 1-2) - Neurotoxicity/excitability: elevated GAA is considered neurotoxic and may perturb inhibitory neurotransmission, with mechanistic support via GABAA receptor mimicry. (ream2023evidenceandrecommendation pages 1-3, marten2024longtermfollowup pages 7-7)

5.4 Clinical manifestation and long-term course - Progressive neurodevelopmental phenotype: hypotonia, developmental delay/intellectual disability, severe speech impairment, epilepsy, behavioral problems, and movement disorder. (ream2023evidenceandrecommendation pages 1-3, stockleripsiroglu2014guanidinoacetatemethyltransferase(gamt) pages 1-2) - Critical window: The evidence base emphasizes that once significant impairment develops, treatment benefit may be limited; presymptomatic treatment is associated with markedly better outcomes. (ream2023evidenceandrecommendation pages 1-3, ream2023evidenceandrecommendation pages 3-4)

  1. Phenotypic manifestations and mechanism links (HP-style terms)

Key phenotypes (with approximate frequencies from cohorts/reviews) - Global developmental delay / intellectual disability (HP: Global developmental delay; HP: Intellectual disability): 44/48 (~92%) in a 48-person cohort; 100% in a 2023 review table summary. (stockleripsiroglu2014guanidinoacetatemethyltransferase(gamt) pages 1-2, mulik2023creatinedeficiencydisorders pages 2-3) - Severe speech/language impairment (HP: Delayed speech and language development): highlighted as prominent feature. (stockleripsiroglu2014guanidinoacetatemethyltransferase(gamt) pages 1-2, ream2023evidenceandrecommendation pages 1-3) - Seizures/epilepsy (HP: Seizure; HP: Epilepsy): 35/48 (~73%) in cohort; ~70% in 2023 review table; often recurrent seizures clinically. (stockleripsiroglu2014guanidinoacetatemethyltransferase(gamt) pages 1-2, mulik2023creatinedeficiencydisorders pages 2-3, ream2023evidenceandrecommendation pages 1-3) - Behavioral abnormalities (HP: Behavioral abnormality; autism-like features): ~75% in 2023 review table; described as “severe behavioral disorders” in evidence review. (mulik2023creatinedeficiencydisorders pages 2-3, ream2023evidenceandrecommendation pages 1-3) - Movement disorder (HP: Dystonia; HP: Ataxia; HP: Movement abnormality): 13/48 (~27%) in cohort; ~30% in review table; includes dystonia/ataxia. (stockleripsiroglu2014guanidinoacetatemethyltransferase(gamt) pages 1-2, mulik2023creatinedeficiencydisorders pages 2-3, ream2023evidenceandrecommendation pages 1-3) - Hypotonia (HP: Hypotonia): common clinical feature noted in evidence review. (ream2023evidenceandrecommendation pages 1-3)

Mechanistic links (examples) - Seizures plausibly reflect both energetic instability and direct GAA effects on inhibitory neurotransmission; mechanistic support is the cited finding that GAA is a “potent GABAA receptor GABA mimetic.” (marten2024longtermfollowup pages 7-7) - Developmental delay and speech impairment align with creatine’s role in cellular energy metabolism and neurodevelopmental processes. (ream2023evidenceandrecommendation pages 1-3, khoja2022genetherapyfor pages 1-2)

  1. Recent developments and latest research (prioritizing 2023–2024)

7.1 Newborn screening policy and implementation (2023) A major translational development is the US recommendation to add GAMT deficiency to newborn screening: the Advisory Committee on Heritable Disorders in Newborns and Children recommended addition to the Recommended Uniform Screening Panel (RUSP), and “This recommendation was accepted in January 2023.” (ream2023evidenceandrecommendation pages 1-3) The Pediatrics evidence review summarizes why screening is impactful: without screening, diagnosis often occurs after significant neurologic injury, whereas presymptomatic dietary/supplement therapy “appear to substantially improve health and developmental outcomes.” (ream2023evidenceandrecommendation pages 1-3)

7.2 Standardization of variant interpretation (2024) ClinGen expert panel recommendations (2024) for classification of variants in GAMT (and related CCDS genes) aim to harmonize molecular diagnosis and clinical interpretation, which is increasingly important with newborn screening expansion and increased genomic testing. (binsfeld2026acnsdirectedaav9 pages 1-3)

7.3 Long-term clinical monitoring with MR spectroscopy and biochemical correlation (2024) A 2024 long-term follow-up report illustrates long-horizon monitoring using plasma/urine metabolites and in vivo brain 1H-MRS (including incorporation of a GAA signal into MRS quantification), tying therapy regimen to biochemical and brain spectroscopy outcomes over many years. (marten2024longtermfollowup pages 1-2, marten2024longtermfollowup pages 2-4)

7.4 Updated phenotype spectrum synthesis (2024) A 2024 scoping review of 53 cases reported that ~79% developed symptoms before age 5 and found seizures in ~68% and developmental delay in ~84%, reinforcing the typical early-onset neurodevelopmental presentation. (alyazidi2024phenotypicandmolecular pages 1-2)

  1. Current applications and real-world implementations

8.1 Diagnostic workflow in real practice Core biochemical diagnosis uses elevated guanidinoacetate and low creatine in body fluids (plasma/urine/CSF) and low brain creatine on 1H-MRS, followed by genetic confirmation. (mulik2023creatinedeficiencydisorders pages 2-3, marten2024longtermfollowup pages 1-2) Newborn screening integration: GAMT deficiency screening can be added to existing tandem mass spectrometry newborn screening, with about 1 per 100,000 newborns screening positive, and diagnosis then confirmed with elevated guanidinoacetate and low creatine in blood. (ream2023evidenceandrecommendation pages 1-3)

8.2 Therapeutic approach in clinical care (mechanism-based) - Creatine supplementation aims to replete systemic and brain creatine. (mulik2023creatinedeficiencydisorders pages 2-3, marten2024longtermfollowup pages 1-2) - Ornithine supplementation and arginine/protein restriction aim to reduce precursor availability and suppress GAA synthesis (substrate reduction). (mulik2023creatinedeficiencydisorders pages 2-3, ream2023evidenceandrecommendation pages 1-3) - Sodium benzoate is used in some protocols to reduce glycine availability (a precursor), contributing to lowering GAA. (ream2023evidenceandrecommendation pages 1-3, ream2023evidenceandrecommendation pages 3-4)

8.3 Emerging and preclinical “root-cause” approaches A 2022 preclinical study reports AAV-based gene therapy expressing human GAMT with pan-hepatic expression, producing “early and sustained” reduction in GAA, normalization of plasma creatine, and increased cerebral and myocardial creatine, alongside improved behavioral and weight phenotypes in a murine model. (khoja2022genetherapyfor pages 1-2)

  1. Expert opinions / authoritative analysis

The Pediatrics evidence review (American Academy of Pediatrics journal) provides a policy-oriented synthesis concluding that feasibility of tandem-MS screening, low screen-positive rate, and expected benefit of presymptomatic therapy justify inclusion on the RUSP, emphasizing that diagnosis is otherwise delayed and treatment later has limited ability to reverse established impairment. (ream2023evidenceandrecommendation pages 1-3, ream2023evidenceandrecommendation pages 4-6) Long-term follow-up literature emphasizes that therapy improves biochemical abnormalities but may not fully normalize metabolites in all compartments (especially brain), reinforcing the need for early initiation and sustained management and motivating curative strategies. (marten2024longtermfollowup pages 1-2, khoja2022genetherapyfor pages 1-2)

  1. Statistics and data from recent studies (selected)

10.1 Prevalence/incidence and screening yields - Birth prevalence estimate (reviewed): likely between 0.5 and 2 per million live births. (ream2023evidenceandrecommendation pages 1-3) - Screening positive rate: “about 1 per 100,000 newborns” screen positive in newborn screening settings. (ream2023evidenceandrecommendation pages 1-3) - Programmatic case detection examples summarized in 2023: - Australia: 1 case in 1.4 million screened. - Utah: 321,305 screened, 3 referrals, 1 case. - New York: 759,246 screened, 24 referrals, 1 case. (As summarized in the Pediatrics evidence review.) (ream2023evidenceandrecommendation pages 3-4)

10.2 Diagnostic delay (real-world natural history) The Pediatrics evidence review summarizes that symptoms were first noticed at mean ~14 months (range 3–24 months) but mean age at diagnosis was ~8.5 years (range 9 months–25 years) in the published literature it reviewed. (ream2023evidenceandrecommendation pages 3-4)

10.3 Phenotype frequencies - 48-person cohort: developmental delay/intellectual disability 44/48 (~92%); epilepsy 35/48 (~73%); movement disorder 13/48 (~27%). (stockleripsiroglu2014guanidinoacetatemethyltransferase(gamt) pages 1-2) - 2023 review table: seizures ~70%; behavioral disorders ~75%; movement disorders ~30%; developmental delay/cognitive dysfunction/intellectual disability 100%. (mulik2023creatinedeficiencydisorders pages 2-3) - 2024 scoping review: seizures ~68%; developmental delay ~84%; intellectual disability/mental retardation ~43%; ~79% onset before age 5. (alyazidi2024phenotypicandmolecular pages 1-2)

10.4 Treatment dosing and monitoring examples - Reported dosing ranges used in presymptomatic/early regimens include creatine ~400 mg/kg/day and ornithine 100–800 mg/kg/day, with optional sodium benzoate ~100 mg/kg/day and dietary measures. (ream2023evidenceandrecommendation pages 3-4) - A 2024 long-term follow-up case report describes starting creatine 400 mg/kg/day and ornithine 100 mg/kg/day at 15 months and observing clinical improvement after 3 months; it also reports laboratory reference ranges (e.g., urine GAA reference range for age 0–<6 months noted as 4–220 µM/mM creatinine; creatine/creatinine ratio 0.006–1.2 for that age band). (marten2024longtermfollowup pages 2-4)

Knowledge-base oriented annotations (structured summary)

A. Pathophysiology description (knowledge-base narrative) GAMT deficiency is an autosomal recessive inborn error of creatine biosynthesis caused by biallelic pathogenic variants in GAMT, which catalyzes methylation of guanidinoacetate to creatine using SAM. Loss of GAMT produces systemic and cerebral creatine depletion with concomitant guanidinoacetate accumulation in biofluids and brain/CSF, resulting in a combined mechanism of impaired cellular energy buffering (creatine/phosphocreatine shuttle dysfunction) and guanidinoacetate neurotoxicity. Clinical manifestations are dominated by early-onset neurodevelopmental impairment with prominent speech delay, epilepsy, behavioral abnormalities, hypotonia, and movement disorder, with strong evidence that presymptomatic treatment substantially improves outcomes and motivates newborn screening implementation. (ream2023evidenceandrecommendation pages 1-3, marten2024longtermfollowup pages 1-2, marten2024longtermfollowup pages 7-7)

B. Gene/protein annotations (examples) - GAMT (HGNC symbol: GAMT): molecular function—methyltransferase activity; biological process—creatine biosynthesis; disease mechanism—loss-of-function causes low creatine + high GAA. (mulik2023creatinedeficiencydisorders pages 1-2, marten2024longtermfollowup pages 1-2) Related pathway genes for context and differential diagnosis - GATM (AGAT): guanidinoacetate biosynthesis step; pharmacologic/dietary substrate reduction targets this step indirectly. (mulik2023creatinedeficiencydisorders pages 1-2) - SLC6A8: creatine transport into cells/brain; affects effectiveness of creatine repletion strategies in CCDS broadly. (mulik2023creatinedeficiencydisorders pages 1-2, khoja2022genetherapyfor pages 1-2)

C. Phenotype associations (HP-style; non-exhaustive) - HP: Global developmental delay; HP: Intellectual disability (stockleripsiroglu2014guanidinoacetatemethyltransferase(gamt) pages 1-2, mulik2023creatinedeficiencydisorders pages 2-3) - HP: Seizure / HP: Epilepsy (stockleripsiroglu2014guanidinoacetatemethyltransferase(gamt) pages 1-2, mulik2023creatinedeficiencydisorders pages 2-3) - HP: Abnormality of movement / HP: Dystonia / HP: Ataxia (ream2023evidenceandrecommendation pages 1-3, stockleripsiroglu2014guanidinoacetatemethyltransferase(gamt) pages 1-2) - HP: Behavioral abnormality (ream2023evidenceandrecommendation pages 1-3, mulik2023creatinedeficiencydisorders pages 2-3) - HP: Hypotonia (ream2023evidenceandrecommendation pages 1-3)

D. Cell type involvement (CL-style; mechanistic emphasis) - CL: neuron; CL: astrocyte; CL: brain microvascular endothelial cell (as a conceptual schema for compartmentalized creatine synthesis/transport underlying CNS vulnerability and incomplete CNS repletion). (binsfeld2026acnsdirectedaav9 pages 1-3, khoja2022genetherapyfor pages 1-2)

E. Anatomical locations (UBERON-style) - UBERON: brain; UBERON: basal ganglion (marten2024longtermfollowup pages 1-2) - UBERON: liver; UBERON: heart/myocardium (khoja2022genetherapyfor pages 1-2)

F. Chemical entities (CHEBI-style) - CHEBI: creatine; CHEBI: guanidinoacetate/guanidinoacetic acid; CHEBI: S-adenosylmethionine; CHEBI: ornithine; CHEBI: sodium benzoate. (mulik2023creatinedeficiencydisorders pages 1-2, ream2023evidenceandrecommendation pages 1-3, ream2023evidenceandrecommendation pages 3-4)

Evidence items (with publication date and URL; PMIDs)

Note on PMIDs: The retrieved full-text excerpts frequently contain DOI and URL metadata but did not consistently include PMIDs. Where PMIDs are required, consult PubMed using DOI-to-PMID mapping for each citation below.

1) Newborn screening evidence and epidemiology - Ream MA et al. “Evidence and Recommendation for Guanidinoacetate Methyltransferase Deficiency Newborn Screening.” Pediatrics. Published July 2023. https://doi.org/10.1542/peds.2023-062100 (ream2023evidenceandrecommendation pages 1-3, ream2023evidenceandrecommendation pages 3-4, ream2023evidenceandrecommendation pages 4-6)

2) 2024 long-term follow-up, MRS/biochemical correlation - Marten LM et al. “Long term follow-up in GAMT deficiency – Correlation of therapy regimen, biochemical and in vivo brain proton MR spectroscopy data.” Molecular Genetics and Metabolism Reports. Published March 2024. https://doi.org/10.1016/j.ymgmr.2024.101053 (marten2024longtermfollowup pages 1-2, marten2024longtermfollowup pages 2-4)

3) 2023 clinical review (phenotypes, biomarkers, treatment dosing) - Mulik C, Mercimek-Andrews S. “Creatine Deficiency Disorders: Phenotypes, Genotypes, Diagnosis, and Treatment Outcomes.” Turkish Archives of Pediatrics. Published March 2023. https://doi.org/10.5152/turkarchpediatr.2023.23022 (mulik2023creatinedeficiencydisorders pages 2-3)

4) Cohort outcomes and diagnosis/treatment recommendations (landmark) - Stöckler-Ipsiroglu S et al. “Guanidinoacetate methyltransferase (GAMT) deficiency: outcomes in 48 individuals and recommendations for diagnosis, treatment and monitoring.” Molecular Genetics and Metabolism. Published January 2014. https://doi.org/10.1016/j.ymgme.2013.10.018 (stockleripsiroglu2014guanidinoacetatemethyltransferase(gamt) pages 1-2)

5) 2024 phenotype spectrum synthesis (scoping review) - Alyazidi AS et al. “Phenotypic and Molecular Spectrum of Guanidinoacetate N-Methyltransferase Deficiency … Scoping Review of 53 Cases …” Journal of Microscopy and Ultrastructure. Published December 2024. https://doi.org/10.4103/jmau.jmau_16_22 (alyazidi2024phenotypicandmolecular pages 1-2)

6) Emerging preclinical therapy - Khoja S et al. “Gene therapy for guanidinoacetate methyltransferase deficiency restores cerebral and myocardial creatine while resolving behavioral abnormalities.” Molecular Therapy – Methods & Clinical Development. Published June 2022. https://doi.org/10.1016/j.omtm.2022.03.015 (khoja2022genetherapyfor pages 1-2)

Visual evidence retrieved - Table image (Pediatrics 2023) supporting improved outcomes with early-treated vs later-treated siblings (cropped artifact from the paper): (ream2023evidenceandrecommendation media 0689e046)

Limitations of this report (due to retrievable evidence constraints)

  • MONDO and Orphanet identifiers were not present in the retrieved full-text excerpts and thus are not reported.
  • PMIDs were not consistently available in the extracted text chunks; DOIs and URLs are provided for PubMed cross-mapping.
  • Some requested quantitative endpoints (e.g., standardized neurodevelopmental test score effect sizes across cohorts) were not present in the accessible excerpts; however, multiple sources provide outcome directionality and early-treatment benefit trends. (ream2023evidenceandrecommendation pages 1-3, stockleripsiroglu2014guanidinoacetatemethyltransferase(gamt) pages 1-2, ream2023evidenceandrecommendation pages 3-4)

References

  1. (ream2023evidenceandrecommendation pages 1-3): Margie A. Ream, Wendy K.K. Lam, Scott D. Grosse, Jelili Ojodu, Elizabeth Jones, Lisa A. Prosser, Angela M. Rose, Anne Marie Comeau, Susan Tanksley, Cynthia M. Powell, and Alex R. Kemper. Evidence and recommendation for guanidinoacetate methyltransferase deficiency newborn screening. Pediatrics, Jul 2023. URL: https://doi.org/10.1542/peds.2023-062100, doi:10.1542/peds.2023-062100. This article has 15 citations and is from a highest quality peer-reviewed journal.

  2. (alyazidi2024phenotypicandmolecular pages 1-2): Anas S. Alyazidi, Osama Y. Muthaffar, Mohammed K. Shawli, Renad A. Ahmed, Yara Fahad Aljefri, Layan Saleh Baaishrah, Abdulaziz T. Jambi, and Fahad A. Alotibi. Phenotypic and molecular spectrum of guanidinoacetate n-methyltransferase deficiency: an analytical study of a case series and a scoping review of 53 cases of guanidinoacetate n-methyltransferase. Journal of Microscopy and Ultrastructure, 12(2):81-90, Dec 2024. URL: https://doi.org/10.4103/jmau.jmau_16_22, doi:10.4103/jmau.jmau_16_22. This article has 2 citations.

  3. (binsfeld2026acnsdirectedaav9 pages 1-3): Robyn Binsfeld, Troy Webster, Ilona Tkachyova, Michael Tropak, Melissa Mitchell, Tesla Peretti, Andreas Schulze, and Jagdeep S. Walia. A cns-directed, aav9 gene therapy restores expression and biochemical function of guanidinoacetate methyltransferase in models of gamt deficiency. International Journal of Molecular Sciences, 27:1035, Jan 2026. URL: https://doi.org/10.3390/ijms27021035, doi:10.3390/ijms27021035. This article has 0 citations.

  4. (mulik2023creatinedeficiencydisorders pages 2-3): Crystal Mulik and Saadet Mercimek-Andrews. Creatine deficiency disorders: phenotypes, genotypes, diagnosis, and treatment outcomes. Turkish Archives of Pediatrics, 58:129-135, Mar 2023. URL: https://doi.org/10.5152/turkarchpediatr.2023.23022, doi:10.5152/turkarchpediatr.2023.23022. This article has 11 citations.

  5. (mulik2023creatinedeficiencydisorders pages 1-2): Crystal Mulik and Saadet Mercimek-Andrews. Creatine deficiency disorders: phenotypes, genotypes, diagnosis, and treatment outcomes. Turkish Archives of Pediatrics, 58:129-135, Mar 2023. URL: https://doi.org/10.5152/turkarchpediatr.2023.23022, doi:10.5152/turkarchpediatr.2023.23022. This article has 11 citations.

  6. (marten2024longtermfollowup pages 1-2): Lara M. Marten, Ralph Krätzner, Gajja S. Salomons, Matilde Fernandez Ojeda, Peter Dechent, Jutta Gärtner, Peter Huppke, and Steffi Dreha-Kulaczewski. Long term follow-up in gamt deficiency – correlation of therapy regimen, biochemical and in vivo brain proton mr spectroscopy data. Molecular Genetics and Metabolism Reports, 38:101053, Mar 2024. URL: https://doi.org/10.1016/j.ymgmr.2024.101053, doi:10.1016/j.ymgmr.2024.101053. This article has 7 citations.

  7. (khoja2022genetherapyfor pages 1-2): Suhail Khoja, Jenna Lambert, Matthew Nitzahn, Adam Eliav, YuChen Zhang, Mikayla Tamboline, Colleen T. Le, Eram Nasser, Yunfeng Li, Puja Patel, Irina Zhuravka, Lindsay M. Lueptow, Ilona Tkachyova, Shili Xu, Itzhak Nissim, Andreas Schulze, and Gerald S. Lipshutz. Gene therapy for guanidinoacetate methyltransferase deficiency restores cerebral and myocardial creatine while resolving behavioral abnormalities. Molecular Therapy - Methods & Clinical Development, 25:278-296, Jun 2022. URL: https://doi.org/10.1016/j.omtm.2022.03.015, doi:10.1016/j.omtm.2022.03.015. This article has 15 citations.

  8. (stockleripsiroglu2014guanidinoacetatemethyltransferase(gamt) pages 1-2): Sylvia Stockler-Ipsiroglu, Clara van Karnebeek, Nicola Longo, G. Christoph Korenke, Saadet Mercimek-Mahmutoglu, Iris Marquart, Bruce Barshop, Christiane Grolik, Andrea Schlune, Brad Angle, Helena Caldeira Araújo, Turgay Coskun, Luisa Diogo, Michael Geraghty, Goknur Haliloglu, Vassiliki Konstantopoulou, Vincenzo Leuzzi, Alina Levtova, Jennifer MacKenzie, Bruno Maranda, Aizeddin A. Mhanni, Grant Mitchell, Andrew Morris, Theresa Newlove, Deborah Renaud, Fernando Scaglia, Vassili Valayannopoulos, Francjan J. van Spronsen, Krijn T. Verbruggen, Nataliya Yuskiv, William Nyhan, and Andreas Schulze. Guanidinoacetate methyltransferase (gamt) deficiency: outcomes in 48 individuals and recommendations for diagnosis, treatment and monitoring. Molecular genetics and metabolism, 111 1:16-25, Jan 2014. URL: https://doi.org/10.1016/j.ymgme.2013.10.018, doi:10.1016/j.ymgme.2013.10.018. This article has 163 citations and is from a peer-reviewed journal.

  9. (ream2023evidenceandrecommendation pages 3-4): Margie A. Ream, Wendy K.K. Lam, Scott D. Grosse, Jelili Ojodu, Elizabeth Jones, Lisa A. Prosser, Angela M. Rose, Anne Marie Comeau, Susan Tanksley, Cynthia M. Powell, and Alex R. Kemper. Evidence and recommendation for guanidinoacetate methyltransferase deficiency newborn screening. Pediatrics, Jul 2023. URL: https://doi.org/10.1542/peds.2023-062100, doi:10.1542/peds.2023-062100. This article has 15 citations and is from a highest quality peer-reviewed journal.

  10. (marten2024longtermfollowup pages 7-7): Lara M. Marten, Ralph Krätzner, Gajja S. Salomons, Matilde Fernandez Ojeda, Peter Dechent, Jutta Gärtner, Peter Huppke, and Steffi Dreha-Kulaczewski. Long term follow-up in gamt deficiency – correlation of therapy regimen, biochemical and in vivo brain proton mr spectroscopy data. Molecular Genetics and Metabolism Reports, 38:101053, Mar 2024. URL: https://doi.org/10.1016/j.ymgmr.2024.101053, doi:10.1016/j.ymgmr.2024.101053. This article has 7 citations.

  11. (marten2024longtermfollowup pages 2-4): Lara M. Marten, Ralph Krätzner, Gajja S. Salomons, Matilde Fernandez Ojeda, Peter Dechent, Jutta Gärtner, Peter Huppke, and Steffi Dreha-Kulaczewski. Long term follow-up in gamt deficiency – correlation of therapy regimen, biochemical and in vivo brain proton mr spectroscopy data. Molecular Genetics and Metabolism Reports, 38:101053, Mar 2024. URL: https://doi.org/10.1016/j.ymgmr.2024.101053, doi:10.1016/j.ymgmr.2024.101053. This article has 7 citations.

  12. (ream2023evidenceandrecommendation pages 4-6): Margie A. Ream, Wendy K.K. Lam, Scott D. Grosse, Jelili Ojodu, Elizabeth Jones, Lisa A. Prosser, Angela M. Rose, Anne Marie Comeau, Susan Tanksley, Cynthia M. Powell, and Alex R. Kemper. Evidence and recommendation for guanidinoacetate methyltransferase deficiency newborn screening. Pediatrics, Jul 2023. URL: https://doi.org/10.1542/peds.2023-062100, doi:10.1542/peds.2023-062100. This article has 15 citations and is from a highest quality peer-reviewed journal.

  13. (ream2023evidenceandrecommendation media 0689e046): Margie A. Ream, Wendy K.K. Lam, Scott D. Grosse, Jelili Ojodu, Elizabeth Jones, Lisa A. Prosser, Angela M. Rose, Anne Marie Comeau, Susan Tanksley, Cynthia M. Powell, and Alex R. Kemper. Evidence and recommendation for guanidinoacetate methyltransferase deficiency newborn screening. Pediatrics, Jul 2023. URL: https://doi.org/10.1542/peds.2023-062100, doi:10.1542/peds.2023-062100. This article has 15 citations and is from a highest quality peer-reviewed journal.